Plus Interest Income from 2010 to 2026

PSTV Stock

USD 0.28 0.01 3.45%

Plus Therapeutics Interest Income yearly trend continues to be fairly stable with very little volatility. Interest Income is likely to outpace its year average in 2026. Interest Income is income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments. View All Fundamentals

Interest Income

First Reported

2019-03-31

Previous Quarter

27 K

Current Value

59 K

Quarterly Volatility

62.3 K

Covid

Interest Hikes

Check Plus Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Plus Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 2.3 M, Selling General Administrative of 10.1 M or Selling And Marketing Expenses of 637 K, as well as many indicators such as Price To Sales Ratio of 1.12, Dividend Yield of 0.0 or Days Sales Outstanding of 42.94. Plus financial statements analysis is a perfect complement when working with Plus Therapeutics Valuation or Volatility modules.

Build AI portfolio with Plus Stock

Check out the analysis of Plus Therapeutics Correlation against competitors.

For more information on how to buy Plus Stock please use our How to Invest in Plus Therapeutics guide.

The evolution of Interest Income for Plus Therapeutics provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Plus Therapeutics compares to historical norms and industry peers.

Latest Plus Therapeutics' Interest Income Growth Pattern

Below is the plot of the Interest Income of Plus Therapeutics over the last few years. It is income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments. Plus Therapeutics' Interest Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Plus Therapeutics' overall financial position and show how it may be relating to other accounts over time.

Interest Income

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Interest Income

Timeline

Plus Interest Income Regression Statistics

	Arithmetic Mean	1,285,731
	Geometric Mean	314,433
	Coefficient Of Variation	123.72
	Mean Deviation	1,471,249
	Median	273,000
	Standard Deviation	1,590,769
	Sample Variance	2.5T
	Range	3.4M
	R-Value	(0.80)
	Mean Square Error	989.2B
	R-Squared	0.63
	Significance	0.0001
	Slope	(250,739)
	Total Sum of Squares	40.5T

Plus Interest Income History

	2026	352.7 K
	2025	245.7 K
	2024	273 K
	2023	400 K
	2022	147 K
	2020	50 K
	2019	55 K

Other Fundumenentals of Plus Therapeutics

Net Interest Income

Plus Therapeutics Interest Income component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Total Liab	Total Current Assets	Retained Earnings	Net Receivables	Short Term Investments	Short Term Debt	Common Stock	Current Deferred Revenue	Accounts Payable	Good Will	Intangible Assets	Net Tangible Assets	Long Term Debt	Long Term Debt Total	Capital Surpluse	Property Plant Equipment	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.62	0.08	0.81	0.91	0.19	0.65	-0.47	0.38	0.45	0.35	0.38	0.64	0.63	-0.24	0.54	0.59	-0.61	-0.23	0.75	0.16	0.33
Total Stockholder Equity	0.62		-0.29	0.07	0.56	0.15	0.1	-0.21	0.15	0.24	0.21	0.09	0.42	0.34	0.19	0.16	0.21	-0.27	0.05	0.72	0.49	0.43
Net Debt	0.08	-0.29		0.31	-0.24	0.12	0.29	0.01	0.52	-0.45	-0.44	0.02	0.34	0.72	-0.37	0.15	0.24	-0.22	0.04	0.14	-0.68	-0.21
Total Liab	0.81	0.07	0.31		0.75	0.12	0.75	-0.48	0.37	0.41	0.29	0.45	0.49	0.54	-0.41	0.53	0.56	-0.55	-0.29	0.39	-0.2	0.15
Total Current Assets	0.91	0.56	-0.24	0.75		0.17	0.65	-0.45	0.24	0.61	0.51	0.37	0.47	0.31	-0.13	0.54	0.54	-0.55	-0.35	0.58	0.32	0.33
Retained Earnings	0.19	0.15	0.12	0.12	0.17		0.41	0.75	-0.06	0.29	0.48	-0.79	0.73	0.31	-0.23	0.81	0.82	-0.82	-0.51	0.62	-0.13	0.16
Net Receivables	0.65	0.1	0.29	0.75	0.65	0.41		-0.13	0.33	0.27	0.23	0.1	0.55	0.5	-0.24	0.75	0.74	-0.73	-0.59	0.42	-0.14	0.09
Short Term Investments	-0.47	-0.21	0.01	-0.48	-0.45	0.75	-0.13		-0.35	-0.08	0.17	-0.99	0.24	-0.12	-0.02	0.33	0.32	-0.3	-0.28	0.11	-0.13	0.01
Short Term Debt	0.38	0.15	0.52	0.37	0.24	-0.06	0.33	-0.35		-0.2	-0.28	0.31	0.18	0.53	-0.48	-0.04	0.04	-0.15	0.3	0.29	-0.16	-0.11
Common Stock	0.45	0.24	-0.45	0.41	0.61	0.29	0.27	-0.08	-0.2		0.97	0.06	0.26	-0.22	-0.05	0.38	0.37	-0.37	-0.3	0.22	-0.04	0.06
Current Deferred Revenue	0.35	0.21	-0.44	0.29	0.51	0.48	0.23	0.17	-0.28	0.97		-0.19	0.33	-0.23	-0.06	0.46	0.46	-0.46	-0.36	0.27	-0.05	0.07
Accounts Payable	0.38	0.09	0.02	0.45	0.37	-0.79	0.1	-0.99	0.31	0.06	-0.19		-0.32	0.06	0.06	-0.38	-0.38	0.38	0.3	-0.23	0.04	-0.06
Good Will	0.64	0.42	0.34	0.49	0.47	0.73	0.55	0.24	0.18	0.26	0.33	-0.32		0.74	-0.35	0.79	0.86	-0.84	-0.39	0.83	-0.16	0.23
Intangible Assets	0.63	0.34	0.72	0.54	0.31	0.31	0.5	-0.12	0.53	-0.22	-0.23	0.06	0.74		-0.31	0.47	0.57	-0.57	-0.13	0.71	-0.23	0.21
Net Tangible Assets	-0.24	0.19	-0.37	-0.41	-0.13	-0.23	-0.24	-0.02	-0.48	-0.05	-0.06	0.06	-0.35	-0.31		-0.21	-0.24	0.34	0.05	-0.28	0.16	0.06
Long Term Debt	0.54	0.16	0.15	0.53	0.54	0.81	0.75	0.33	-0.04	0.38	0.46	-0.38	0.79	0.47	-0.21		0.99	-0.92	-0.78	0.64	-0.06	0.16
Long Term Debt Total	0.59	0.21	0.24	0.56	0.54	0.82	0.74	0.32	0.04	0.37	0.46	-0.38	0.86	0.57	-0.24	0.99		-0.95	-0.72	0.71	-0.14	0.2
Capital Surpluse	-0.61	-0.27	-0.22	-0.55	-0.55	-0.82	-0.73	-0.3	-0.15	-0.37	-0.46	0.38	-0.84	-0.57	0.34	-0.92	-0.95		0.6	-0.76	0.06	-0.24
Property Plant Equipment	-0.23	0.05	0.04	-0.29	-0.35	-0.51	-0.59	-0.28	0.3	-0.3	-0.36	0.3	-0.39	-0.13	0.05	-0.78	-0.72	0.6		-0.23	0.01	-0.14
Net Invested Capital	0.75	0.72	0.14	0.39	0.58	0.62	0.42	0.11	0.29	0.22	0.27	-0.23	0.83	0.71	-0.28	0.64	0.71	-0.76	-0.23		0.25	0.39
Net Working Capital	0.16	0.49	-0.68	-0.2	0.32	-0.13	-0.14	-0.13	-0.16	-0.04	-0.05	0.04	-0.16	-0.23	0.16	-0.06	-0.14	0.06	0.01	0.25		0.38
Capital Stock	0.33	0.43	-0.21	0.15	0.33	0.16	0.09	0.01	-0.11	0.06	0.07	-0.06	0.23	0.21	0.06	0.16	0.2	-0.24	-0.14	0.39	0.38

Click cells to compare fundamentals

About Plus Therapeutics Financial Statements

Plus Therapeutics investors use historical fundamental indicators, such as Plus Therapeutics' Interest Income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Plus Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Interest Income	245.7 K	352.7 K
Net Interest Income	-4 M	-3.8 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Plus Stock Analysis

When running Plus Therapeutics' price analysis, check to measure Plus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Plus Therapeutics is operating at the current time. Most of Plus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Plus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Plus Therapeutics' price. Additionally, you may evaluate how the addition of Plus Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Plus Interest Income from 2010 to 2026

Latest Plus Therapeutics' Interest Income Growth Pattern

Plus Interest Income Regression Statistics

Plus Interest Income History

Other Fundumenentals of Plus Therapeutics

Plus Therapeutics Interest Income component correlations

About Plus Therapeutics Financial Statements

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Plus Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY